parently do not affect NTG-induced vasorelaxation. In vivo data on the relations between sulfhydryl compound levels and vascular nitrate responsiveness have not been reported.
To study these relations, we determined the effect of a specific intracellular cysteine donor and an extracellular and intracellular cysteine donor on plasma and vascular cysteine and GSH concentrations and on the degree of NTG-induced hypotension in conscious rats. In addition, the effect of GSH depletion was investigated in rats treated with a specific GSH synthesis inhibitor. The combined effect of GSH depletion and subsequent cysteine donor administration on sulfhydryl compound levels and NTG responsiveness was also examined.
Methods

Animals
For chronic catheterization, female Wistar rats (weight, 200-260 g) were anesthetized with 1-3% halothane and N20/02 (2:1). One catheter (medical grade Tygon catheters) was implanted with its tip in the ascending aorta through the left carotid artery, and two catheters were placed in the superior vena cava via the left jugular vein. Catheters were filled with a solution of 50% glucose and 500 IU/ml heparin and plugged with a nylon pin. Each catheter was externalized through the back in the neck region. After catheter implantation, the rats were housed individually and exposed to a 12-hour light-12-hour dark cycle and with free access to a standard rat chow and tap water. Postoperatively, rats were allowed to recover from surgery until they had regained their preoperative weights and appeared healthy (6-8 days) . Details regarding this rat model with chronically catheterized conscious rats have been described previously." Drugs NTG (100 mg/ml) was dissolved in 5% glucose. N-Acetyl-L-cysteine (NAC), N-acetylserine (NAS), and L-buthionine-[S,R]-sulfoximine (BSO) were purchased from Sigma Chemical Co., St. Louis, Mo. L-2-Oxothiazolidine-4-carboxylic acid (OXO) was obtained from Bachem AG, Bubendorf, Switzerland. All solutions were adjusted to pH 7. 4 with NaOH and prepared in 0.9% NaCl.
NAS. NAS is identical to NAC except that it contains a hydroxy group in place of a sulfhydryl group, and any differences in response to NAC and NAS are probably due to this difference.
NAC. GSH levels may be increased by several methods. Cysteine is usually the limiting amino acid in GSH synthesis, but its administration is toxic. Administered NAC leads to increased cysteine levels after deacetylation (primarily in the kidney) and thus increased GSH levels.12 '13 OXO. OXO is a nonthiol, nontoxic cysteine delivery drug and is readily transported into cells and converted into cysteine by 5-oxoprolinase, a widely distributed intracellular enzyme.13,14 OXO is a specific intracellular sulfhydryl donor (whereas NAC has both intracellular and extracellular sulfhydryl donor properties) and is more effective in increasing intracellular cysteine and GSH content than NAC13 (Figure 1) . BSO . GSH is synthesized intracellularly by the consecutive actions of gamma-glutamylcysteine synthetase and GSH synthetase.13 Gamma-glutamylcysteine synthetase is the rate-limiting step in GSH synthesis and is feedback inhibited by the end product, GSH.13,15 Availability of substrates, especially cysteine, may also regulate cellular GSH levels. Cellular GSH is normally transported out of cells.15 Cellular GSH levels are lowered by the administration of BSO, a specific inhibitor of gamma-glutamylcysteine synthetase16 (Figure 1 16 hours, and 24 hours). Two hours after the last BSO dose, the NTG bolus injections were repeated, and the blood pressure changes were monitored.
Sulfhydryl compound administration in GSH-depleted rats. Two additional groups of rats were treated with BSO as described. Immediately after the last BSO dose, NAC (n=8) or OXO (n=8) was infused at a dose of 5 mmol. kg-'. hr1' for 3 hours. NTG bolus injections were repeated after 2 hours of infusion. were removed to determine vascular (intracellular) cysteine and GSH levels.
Measurement of Cysteine and GSH Levels
Reduced glutathione was determined by a modification of the method described by Fahey and Newton. 17 Arterial blood was placed in prechilled tubes together with serine/borate at a final concentration of 20 mM, spun in a fast accelerating centrifuge, and 100 ,l of plasma was obtained within 2 minutes for derivatization with monobromobimane (Calbiochem). Vascular tissue was immediately frozen in liquid nitrogen, pulverized in liquid nitrogen, treated with serine/borate for immediate derivatization with monobromobimane, and deproteinized.17
Ten microliters of the samples was injected into a Merck/Hitachi high-performance liquid chromatography gradient system consisting of a model L-6200 pump, a model L-6000 pump, a model AS-2000 autosampler, and a model F-1050 fluorescent detector set at 415-nm excitation and 490-nm emission. The system was connected to a PC-based high-performance liquid chromatography manager (Hitachi model d-6000, Chromatography Data Station Software) for automatization and integration. Gradient elution was performed with two solvents. Solvent A was prepared from 2.5 ml acetic acid, 50 ml acetonitrile, 7.03 g sodium perchlorate, and water to a total volume of 1 1; the pH was adjusted to 3.4. Solvent B was prepared from 2.5 ml acetic acid, 7 (Figure 2 ). Neither OXO nor the nonthiol NAS influenced the pharmacodynamic response to NTG (Figure 2 ). Therefore, intracellular thiol levels above the normal range (OXO) do not alter NTG responsiveness. Thus, the increased hypotensive effect of NTG (approximately 19%) after NAC infusion probably depends on the marked increase in plasma cysteine and GSH produced by NAC rather than by the NAC-induced changes in intracellular cysteine and GSH levels.
Effect of BSO Treatment on Cysteine and GSH Content and NTG Responsiveness
The major source of plasma GSH is the liver, and the observed small increase in plasma GSH suggests that liver gamma-glutamylcysteine synthetase was not fully inhibited by BSO (despite a rigorous dose regimen) in this experiment. However, compared with control levels, BSO significantly lowered intracellular GSH content (Table 1) . GSH levels in vena cava were significantly lower than in aorta, suggesting a likely difference in susceptibility to BSO-induced GSH depletion in the two vascular beds. Cysteine levels in aorta were not significantly altered. As shown in Figures 3 and 4 , GSH depletion induced by giving BSO significantly decreased the hypotensive effect of NTG (43%).
Effect of Sulfhydryl Compound Supplementation in GSH-Depleted (BSO-Treated) Animals
As expected, NAC or OXO infusion in BSO-pretreated animals did not normalize the low intracellular GSH levels (Table 1) . However, slightly increased intracellular GSH levels after BSO+NAC and BSO+OXO compared with BSO treatment suggests that not all vascular gamma-glutamylcysteine synthetase was inhibited by BSO. Intracellular cysteine and plasma levels of cysteine were significantly increased because cysteine cannot be used for GSH synthesis.
The potentiated NTG response seen in animals treated with NAC alone (Figure 2) is abolished in the BSO+NAC group of animals with low intracellular GSH levels (Figure 4) (Figure 4 ) (vascular GSH levels are comparably low), it is likely that the very high levels of intracellular cysteine and/or plasma cysteine and GSH may compensate some of the effects of intracellular GSH depletion.
Discussion
In the current study, the pharmacodynamic response to NTG during treatment with different sulfhydrylmodulating drugs has been correlated with actual plasma and tissue thiol levels, thus providing new information about nitrate-thiol interactions in vivo. The hypotensive effect of NTG in vivo was altered either by depletion of intracellular (vascular) GSH content (which inhibits the response to NTG) or by increasing the extracellular (plasma) cysteine and/or GSH levels (which potentiates the effect of NTG). Clearly, supraphysiologically high intracellular levels of cysteine and GSH are not associated with changes in NTG responsiveness in normal animals ( Figure 5) .
The mechanism by which NTG is metabolized to vasoactive substances in vascular smooth muscle remains a subject of some controversy. At present, hypotheses involve interaction of NTG with intracellular thiols at one or more sites during its biotransformation to vasoactive nitrosothiols.2,18 GSH conjugation and oxidation may be involved in the denitration of NTG to nitrous acid, which then nonenzymatically interacts with another sulfhydryl group to generate S-nitrosothiols. 19, 20 In vitro, cysteine appears to be required for nitrate-induced activation of guanylate cyclase,18 and cysteine and GSH may accelerate the degradation of NTG in plasma. 6 Recently, a direct "one step" conversion of NTG to a nitrosothiol in the presence of cysteine has been proposed. 21 The results in the current study on the effects of NAC and sulfhydryl compound depletion (which has not been investigated previously in vivo) are consistent with and extend these in vitro observations. At present, it is not clear whether this interaction takes place within and/or outside the vascular smooth muscle cell. The present study provides information about the relative contribution of extracellular/intracellular metabolic pathways in vivo.
We find that 1) animals with very high plasma levels of cysteine and GSH and physiological intracellular sulfhydryl levels (after NAC treatment) showed an augmented response to NTG, suggesting that there is an important extracellular NTG-thiol interaction. In vitro studies in which plasma enzyme activity may augment NTG-induced activation of soluble guanylate cyclase in the presence of NAC appear to support this observation.6'22 2) Supraphysiologically high intracellular cysteine and GSH and relatively normal extracellular levels (OXO treatment) do not affect the hypotensive effect of NTG. This implies that intracellular sulfhydryl levels in normal animals are not rate limiting for the conversion of NTG to nitric oxide, an observation in line with findings that elevation of intracellular cysteine levels does not affect NTG-induced relaxation in vitro. 9 3) BSO-induced inhibition of intracellular GSH synthesis significantly lowers intracellular GSH levels in vascular tissue and reduces the hypotensive effect of NTG. This result suggests that a critical amount of intracellular GSH is required for optimal conversion of NTG in vivo. Subsequent treatment with NAC (BSO+NAC group) does not reverse the low GSH levels but provides high levels of intracellular cysteine and high levels of extracellular cysteine and GSH. Although these changes tended to normalize the pharmacodynamic effect of NTG, the NTG-potentiating effect of NAC was abolished. Together, these findings further emphasize that GSH (synthesized from cysteine, glutamate, and glycine within the cells) is found almost exclusively intracellularly and constitutes the major cellular nonprotein sulfhydryl pool. Cysteine is rapidly metabolized, and GSH may be regarded as a storage and transport form of cysteine; cysteine levels in most tissues are present in much lower concentrations (10-100 p.M) than those of GSH (500-10,000 pM).23 A continuous and irreversible transport of GSH out of the cell is the source of extracellular GSH and may augment extracellular sulfhydryl availability by extracellular or membranous metabolism of GSH.15,24 Thus, synthesis and degradation of GSH includes intracellular and extracellular reactions and involves the immediate environment on both sides of the cell membrane'5'24 ( Figure 1) .
Although the levels of GSH and cysteine in plasma are normally very low, it is probable that their concentration in interstitial fluid in proximity to the cell membrane are greater than plasma levels as a consequence of the cellular GSH export process. 24 Recently, it has been reported25 that enzymes involved in the metabolic activation of NTG are located mainly in the cell membrane fragment of vascular smooth muscle cells. One may speculate that the metabolism of NTG may take place at or in near proximity to the cell membrane of the smooth muscle cell and may require an enzyme located on the external surface of the cell membrane and that such metabolism requires continuous export of intracellular GSH (and perhaps membranous degradation of GSH to cysteine). This 
